RBD and Spike DNA-Based Immunization in Rabbits Elicited IgG Avidity Maturation and High Neutralizing Antibody Responses against SARS-CoV-2
Authors:
- Hernan H. M. da CostaHCHernan H. M. da Costa
- Diego J. B. OrtsDODiego J. B. Orts
- Andrew D. MouraAMAndrew D. Moura
- Amaro N. Duarte-NetoADAmaro N. Duarte-Neto
- Cinthya S. CirqueiraCCCinthya S. Cirqueira
- Rodrigo A. RéssioRRRodrigo A. Réssio
- Cristina T. KanamuraCKCristina T. Kanamura
- Karen MiguitaKMKaren Miguita
- Jerenice E. FerreiraJFJerenice E. Ferreira
- Raimunda T. M. SantosRSRaimunda T. M. Santos
- Patricia P. AdrianiPAPatricia P. Adriani
- Jair P. Cunha-JuniorJCJair P. Cunha-Junior
Open Access
Abstract
Neutralizing antibodies (nAbs) are a critical part of coronavirus disease 2019 (COVID-19) research as they are used to gain insight into the immune response to severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) infections. Among the technologies available for generating nAbs, DNA-based immunization methods are an alternative to conventional protocols. In this pilot study, we investigated whether DNA-based immunization by needle injection in rabbits was a viable approach to produce a functional antibody response. We demonstrated that three doses of DNA plasmid carrying the gene encoding the full-length spike protein (S) or the receptor binding domain (RBD) of SARS-CoV-2 induced a time-dependent increase in IgG antibody avidity maturation. Moreover, the IgG antibodies displayed high cross neutralization by live SARS-CoV-2 and pseudoviruses neutralization assays. Thus, we established a simple, low cost and feasible DNA-based immunization protocol in rabbits that elicited high IgG avidity maturation and nAbs production against SARS-CoV-2, highlighting the importance of DNA-based platforms for developing new immunization strategies against SARS-CoV-2 and future emerging epidemics.Keywords
Funding Information
- Conselho Nacional de Desenvolvimento Científico e Tecnológico (130843/2020-2, 440812/2016-0, 88887.703323/2022-00, 88881.130804/2016–01, 88887.506965/2020–0, 88881.130804/2016–01, 17/50333-7)
- Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (130843/2020-2, 440812/2016-0, 88887.703323/2022-00, 88881.130804/2016–01, 88887.506965/2020–0, 88881.130804/2016–01, 17/50333-7)
- Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (130843/2020-2, 440812/2016-0, 88887.703323/2022-00, 88881.130804/2016–01, 88887.506965/2020–0, 88881.130804/2016–01, 17/50333-7)
- São Paulo Research Foundation (130843/2020-2, 440812/2016-0, 88887.703323/2022-00, 88881.130804/2016–01, 88887.506965/2020–0, 88881.130804/2016–01, 17/50333-7)
This publication has 68 references indexed in Scilit:
- A novel neutralizing monoclonal antibody targeting the N-terminal domain of the MERS-CoV spike proteinEmerging Microbes & Infections, 2017
- DNA Vaccine Delivery and Improved ImmunogenicityCurrent Issues in Molecular Biology, 2017
- DNA ImmunizationCurrent Protocols in Microbiology, 2013
- DNA electroporation in rabbits as a method for generation of high-titer neutralizing antiseraHuman Vaccines & Immunotherapeutics, 2013
- Vector Design for Improved DNA Vaccine Efficacy, Safety and ProductionVaccines, 2013
- Correlation between Dengue-Specific Neutralizing Antibodies and Serum Avidity in Primary and Secondary Dengue Virus 3 Natural Infections in HumansPLOS Neglected Tropical Diseases, 2013
- In Vitro Transcription of Long RNA Containing Modified Nucleosides2012
- Antibody Avidity Maturation during Severe Acute Respiratory Syndrome–Associated Coronavirus InfectionThe Journal of Infectious Diseases, 2005
- DNA vaccines: a reviewJournal of Internal Medicine, 2003
- Immunological properties of gene vaccines delivered by different routesBrazilian Journal of Medical and Biological Research, 1999